Dawn C. Buse, PhD

home / authors / dawn-c-buse-phd

Articles

Behavioral and Lifestyle Strategies for Migraine Management

Behavioral and Lifestyle Strategies for Migraine Management

Peter J. Goadsby, MD, PhD, DSc;Dawn C. Buse, PhD;Jelena Pavlovic, MD, PhD;Wade M. Cooper, DO;Paul G. Mathew, MD, DNPAS, FAAN, FAHS
October 28th 2020
Patient Selection for Neuromodulation Devices

Patient Selection for Neuromodulation Devices

Peter J. Goadsby, MD, PhD, DSc;Dawn C. Buse, PhD;Jelena Pavlovic, MD, PhD;Wade M. Cooper, DO;Paul G. Mathew, MD, DNPAS, FAAN, FAHS
October 28th 2020
Role of Neuromodulation for Acute Treatment of Migraine

Role of Neuromodulation for Acute Treatment of Migraine

Peter J. Goadsby, MD, PhD, DSc;Dawn C. Buse, PhD;Jelena Pavlovic, MD, PhD;Wade M. Cooper, DO;Paul G. Mathew, MD, DNPAS, FAAN, FAHS
October 28th 2020
Patient Selection of Novel Therapies for Migraine Treatment

Patient Selection of Novel Therapies for Migraine Treatment

Peter J. Goadsby, MD, PhD, DSc;Dawn C. Buse, PhD;Jelena Pavlovic, MD, PhD;Wade M. Cooper, DO;Paul G. Mathew, MD, DNPAS, FAAN, FAHS
October 28th 2020
Intranasal DHE in Acute Treatment of Migraine

Intranasal DHE in Acute Treatment of Migraine

Peter J. Goadsby, MD, PhD, DSc;Dawn C. Buse, PhD;Jelena Pavlovic, MD, PhD;Wade M. Cooper, DO;Paul G. Mathew, MD, DNPAS, FAAN, FAHS
October 28th 2020
Safety of CGRP Receptor Antagonists vs 5-HT1F Agonists

Safety of CGRP Receptor Antagonists vs 5-HT1F Agonists

Peter J. Goadsby, MD, PhD, DSc;Dawn C. Buse, PhD;Jelena Pavlovic, MD, PhD;Wade M. Cooper, DO;Paul G. Mathew, MD, DNPAS, FAAN, FAHS
October 28th 2020
Use of 5-HT1F Agonists in Acute Treatment of Migraine

Use of 5-HT1F Agonists in Acute Treatment of Migraine

Peter J. Goadsby, MD, PhD, DSc;Dawn C. Buse, PhD;Jelena Pavlovic, MD, PhD;Wade M. Cooper, DO;Paul G. Mathew, MD, DNPAS, FAAN, FAHS
October 28th 2020
Acute Treatment of Migraine: Progress With Novel Medications

Acute Treatment of Migraine: Progress With Novel Medications

Peter J. Goadsby, MD, PhD, DSc;Dawn C. Buse, PhD;Jelena Pavlovic, MD, PhD;Wade M. Cooper, DO;Paul G. Mathew, MD, DNPAS, FAAN, FAHS
October 28th 2020
Evolution of Acute Treatment of Migraine

Evolution of Acute Treatment of Migraine

Peter J. Goadsby, MD, PhD, DSc;Dawn C. Buse, PhD;Jelena Pavlovic, MD, PhD;Wade M. Cooper, DO;Paul G. Mathew, MD, DNPAS, FAAN, FAHS
October 28th 2020
Acute Treatment of Migraine: Traditional Therapies

Acute Treatment of Migraine: Traditional Therapies

Peter J. Goadsby, MD, PhD, DSc;Dawn C. Buse, PhD;Jelena Pavlovic, MD, PhD;Wade M. Cooper, DO;Paul G. Mathew, MD, DNPAS, FAAN, FAHS
October 28th 2020
Unmet Needs in the Management of Migraine

Unmet Needs in the Management of Migraine

Peter J. Goadsby, MD, PhD, DSc;Dawn C. Buse, PhD;Jelena Pavlovic, MD, PhD;Wade M. Cooper, DO;Paul G. Mathew, MD, DNPAS, FAAN, FAHS
October 28th 2020
A Big-Picture Look at the Burden of Migraine

A Big-Picture Look at the Burden of Migraine

Dawn C. Buse, PhD
September 26th 2019

Reducing the frequency of migraine is only 1 step in the process of optimizing management and addressing the disease's impact on patients’ lives.

Latest Updated Articles

FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
Published: March 27th 2025 | Updated: March 28th 2025
FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion Counts
Published: March 4th 2025 | Updated: March 19th 2025
BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion Counts
FDA Approves Vertex Pharmaceuticals' Suzetrigine for Acute Pain Management
Published: January 30th 2025 | Updated: February 21st 2025
FDA Approves Vertex Pharmaceuticals' Suzetrigine for Acute Pain Management
Cerebrospinal Fluid Lipids Shows Promise as Biomarkers for Differentiating NMOSD and MS
Published: February 15th 2025 | Updated: February 18th 2025
Cerebrospinal Fluid Lipids Shows Promise as Biomarkers for Differentiating NMOSD and MS
FDA Approves Apomorphine Infusion Device SPN-830 as New Parkinson Treatment
Published: February 4th 2025 | Updated: February 6th 2025
FDA Approves Apomorphine Infusion Device SPN-830 as New Parkinson Treatment
FDA Approves Axsome Therapeutics’ AXS-07 for Migraine Treatment
Published: January 30th 2025 | Updated: February 4th 2025
FDA Approves Axsome Therapeutics’ AXS-07 for Migraine Treatment
© 2025 MJH Life Sciences

All rights reserved.